U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07701408) titled 'ctDNA and TEP Levels in Colon Cancer' on June 18.
Brief Summary: This interventional cohort study will evaluate circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP) as blood-based biomarkers in adults with stage III colon cancer who are planned to receive neoadjuvant systemic therapy followed by surgical resection.
Treatment will be given according to routine clinical practice and will depend on the biological characteristics of the tumor, including mismatch repair status. Participants will provide additional blood samples at predefined time points before, during, and after treatment and surgery. These samples will be u...